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ABSTRACT 
Cholesterol is a vital compound that can undergo cytochrome P450 (CYP) mediated 
conversion into steroid hormones, bile acids and oxysterols. CYP enzymes are present in all 
human tissues and mediate the metabolism of several endogenous and exogenous compounds 
such as steroids and drugs. Vitamin D status has been shown to be important for several 
biological processes such as drug metabolism, modulation of the immune system and bone 
health. Enzymes in subfamily CYP3A (CYP3A4, CYP3A5, CYP3A7 and CYP3A43) are 
present in liver and intestine and metabolize about 50% of all prescribed drugs. Genetic 
factors, age, sex, ethnicity and environmental factors influence the activity and expression of 
CYP3A enzymes. This cause wide inter-patient variability in CYP3A mediated drug response. 
There are a number of clinical markers to assess the CYP3A activity, e.g. plasma midazolam 
clearance, quinine metabolic ratio and 4-hydroxycholesterol/cholesterol ratio. 
In the present study we have evaluated the plasma levels of 4-hydroxycholesterol and the 4-
hydroxycholesterol/cholesterol ratio as markers of CYP3A activity during enzyme induction by 
a number of drugs (carbamazepine in Papers I and III, rifampicin in Papers IV-V and efavirenz 
in Paper V) and by pregnancy (Paper III). We have also studied the association between 
CYP3A activity and vitamin D status (Paper IV-V). In Paper I, carbamazepine treatment in 
children with epilepsy doubled the plasma levels of 4-hydroxycholesterol within two weeks of 
treatment. The increase was 5 to 10-fold within eight weeks treatment. In Paper III, pregnancy 
increased the 4-hydroxycholesterol/cholesterol ratio and the plasma levels of cholesterol. 
Newborn children had similar CYP3A activity as adults as indicated by similar 4-
hydroxycholesterol/cholesterol ratios. Carbamazepine treatment during pregnancy further 
increased the CYP3A activity in one mother and child. In Papers IV-V, rifampicin-mediated 
CYP3A induction did not affect the plasma levels of 25-hydroxyvitamin D in healthy 
volunteers or in tuberculosis-HIV co-infected patients. In tuberculosis-HIV co-infected patients 
there was a significant negative correlation between the plasma levels of 25-hydroxyvitamin D 
and the 4-hydroxycholesterol/cholesterol ratio already at initiation of treatment (Paper V). 
Efavirenz treatment caused a transient decrease in the plasma levels of 25-hydroxyvitamin D in 
HIV-infected patients (Paper V). 
To summarize, 4-hydroxycholesterol and the 4-hydroxycholesterol/cholesterol ratio are 
useful as markers of CYP3A induction. 4-Hydroxycholesterol is a non-invasive endogenous 
clinical marker that is easy to use also in children and vulnerable patient groups. The blood 
samples can be taken any time of the day regardless of food intake. 
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